Egle names Detheux chairman
Plus: BeiGene adds to commercial leadership, hiring Pfizer veteran Matt Shaulis, and updates from Wells Fargo, Flagship, Alume, Cytek, Aetion and 180 Life Sciences
Egle Therapeutics S.A.S., which is targeting regulatory T cells to treat cancer and autoimmune diseases, named Michel Detheux independent chairman and Mojgan Hossein-Nia board member. Detheux is CEO of iTeos Therapeutics Inc. (NASDAQ:ITOS); Hossein-Nia is head of R&D global portfolio strategy and strategic finance, R&D at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), which invested in Egle’s series A in 2021.
Early this week, BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235) bolstered its North American commercial leadership team with the addition of Matt Shaulis as GM for the continent. Shaulis, who has more than 20 years of global biopharma commercial leadership experience, headed commercial at Hansa Biopharma AB (SSE:HNSA) and spent nearly eight years at Pfizer Inc. (NYSE:PFE), where he directed the U.S. commercialization of oncology blockbusters Ibrance palbociclib and Xtandi enzalutamide and helped lead Pfizer’s integration of Medivation Inc. ...